Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × MCRC × tislelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 54 Carcinoma, Hepatocellular 35 Colorectal Neoplasms 30 Stomach Neoplasms 27 Esophageal Squamous Cell Carcinoma 21 Squamous Cell Carcinoma of Head and Neck 16 Neoplasm Metastasis 13 Esophageal Neoplasms 13 Advanced Solid Tumor 12 Lung Neoplasms 11 Head and Neck Neoplasms 11 Small Cell Lung Carcinoma 9 Nasopharyngeal Carcinoma 9 Triple Negative Breast Neoplasms 8 Recurrence 8 Neoplasms 8 Colonic Neoplasms 8 Cholangiocarcinoma 8 Uterine Cervical Neoplasms 7 Pancreatic Neoplasms 7 Melanoma 7 Rectal Neoplasms 6 Solid Tumor 5 Lymphoma 5 Hodgkin Disease 5 Carcinoma, Transitional Cell 5 Advanced Solid Tumors 5 Urinary Bladder Neoplasms 4 Sarcoma 4 Lymphoma, Extranodal NK-T-Cell 4

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡